scholarly journals Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma

2012 ◽  
Vol 69 (12) ◽  
pp. 1031-1038 ◽  
Author(s):  
Tatjana Ivkovic-Kapicl ◽  
Milana Panjkovic ◽  
Ivan Nikolic ◽  
Dragana Djilas-Ivanovic ◽  
Slavica Knezevic-Usaj
Keyword(s):  
Histological Grade ◽  
Clinicopathological Characteristics ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Her2 Gene ◽  
Receptor Status ◽  
Basal Expression ◽  
Tumor Expression ◽  
Triple Negative Phenotype ◽  
Basal Cytokeratins

Background/Aim. Cytokeratins (CK) 5/6 and 17, myoepithelial markers, are also expressed in a proportion of breast carcinomas. Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that shows common but heterogeneous morphological, genetical, and immunophenotypical features and is associated with poor clinical outcome. The aim of this study was to determine the incidence of basal expression of cytokines CK5/6 and CK17 in the tested samples of ductal invasive breast cancers, as well as to test the presence of a correlation of tumor expression of basal cytokines and clinicopathological prognostic factors: age, the level of histological differentiation, hormone receptor status, HER2 (human epidermal prowth factor receptor 2) protein expresion and HER2 gene amplification in tumorous tissue. Methods. Immunohistochemistry (IHC) was used to evaluate the CK5/6 and CK17 status of 121 ductal invasive breast cancers. The results thus obtained were compared with clinicopathological characteristics. Results. From the 117 analyzed tumor specimens, 22% and 30% were immunohistochemically positive for CK5/6 and CK17, respectively. Basal cytokeratins showed significant inverse relationship with estrogen and progesterone receptor status and HER2 protein expression. CK5/6 and CK17 immunoreactivities were directly associated with triple-negative phenotype and higher histological grade. Conclusion. Our findings are similar to reports that tumours expression of basal cytokeratins are correlated with adverse pathological parameters. Given the limited number of emerging therapeutic targets in these tumors, routine IHC identification of basal-like subtype as a poor prognostic group of breast cancer could be based on the expression of basal CKs.

Analysis of Low Estrogen Receptor (ER+) Breast Carcinomas in a Large Community Breast Cancer Center in Northern California

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S26-S27
Author(s):  
G Bulusu ◽  
K Duncan ◽  
A Wheeler
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Histological Grade ◽  
Statistical Significance ◽  
Cancer Center ◽  
Pathology Report ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Ki 67 ◽  
Er Positive

Abstract Introduction/Objective Estrogen Receptor (ER) expression in breast cancers is a crucial factor for endocrine therapy in patients with tumors expressing ER in ≥1% of tumor cells. The 2019 guidelines published by ASCO/CAP states that breast cancers that have a 1% to 10% of cells staining Estrogen Receptor (ER) positive should be reported as ER Low Positive cases. This study aims to address this subset of low-positive ER tumors and compare the clinical features to other known breast cancer subtypes. Methods/Case Report We conducted a retrospective review of a prospectively maintained breast cancer registry from 2013 to 2021 at Mills-Peninsula Medical Center, a Sutter Health Affiliate. The study reviewed patient charts with respect to the pathology report, operative report, chemotherapy regimen, and clinical outcomes. Statistical analyses were conducted using R Project for Statistical Coding, with The Student’s T-test used to compare continuous variables. Two-sided P values less than 0.05 indicate statistical significance. Results (if a Case Study enter NA) Our study identified 1316 cases of invasive breast carcinomas, of which 29 (2.16%) demonstrated ER Low-Positive expression. We aimed to evaluate the clinical and pathological features, such as histological grade, ER, PR, HER-2, Ki-67%, and patient age for these tumors. We found that ER Low-Positive tumors demonstrated higher mean histological grade morphology (2.5 out of 3, p<0.001) that was similar to that of Triple Negative Breast Cancers (TNBC) (3 of 3, p<0.001) than to High ER-Positive (1.6 of 3, p<0.001) cancers. Further observations, through examining proliferation rates by utilizing the Ki-67 index, indicate comparative trends between the ER Low-Positive cohort and the TNBC cohort. Conclusion The results suggest that the ER Low-Positive carcinomas, despite reported as ER-positive cases, present with similar clinicopathological features to those of ER-negative tumors. Through this study and future research, we would like to emphasize a stricter set of guidelines that can be adopted to reduce variability for reporting biomarkers. This standardization will allow oncologists to provide more appropriate treatment options and improve the quality of patient care.

scholarly journals HISTOPATOLOGICAL SPECTRUM OF BREAST CARCINOMAS AND CORRELATION OF HISTOLOGICAL GRADE WITH ER, PR, HER2NEU STATUS IN A TERTIARY CARE CENTRE OF EASTERN INDIA

2019 ◽  
pp. 1-3
Author(s):  
Moumita Paul ◽  
Neepamanjari Barman* ◽  
Moumita Maiti ◽  
Ranu Sarkar
Keyword(s):  
Complex Disease ◽  
Histological Grade ◽  
Target Therapy ◽  
Tertiary Care ◽  
Response To Treatment ◽  
Treatment Modalities ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Tertiary Care Centre ◽  
Epidermal Growth

Background: Carcinoma of the breast is a truly complex disease with a large intratumoral heterogeneity, leading to markedly variable clinical course and response to treatment modalities. Prognosis and management of breast cancer are influenced by variables such as stage, grade, hormone receptor status of estrogen(ER), progesterone(PR) and Human epidermal growth factor receptor2 (HER2/neu) over expression. Aims and Objectives:To highlight the histomorphological spectrum of breast carcinomas and their ER,PR, HER2NEU status. And also to find out correlation between their histological grade and the hormone status . Materials and Methods - 115 breast carcinomas were clinicopathologically and immunohistochemically analyzed in which assessment of Her2/neu, ER, PR had been performed prospectively. Statistical analysis was then used to correlate the above observation. Conclusion: This study highlights the importance of histopathology and immunohistochemistry in breast cancers not only in diagnosing the lesion but also in predicting the prognosis and target therapy.

scholarly journals HISTOPATOLOGICAL SPECTRUM OF BREAST CARCINOMAS AND CORRELATION OF HISTOLOGICAL GRADE WITH ER, PR, HER2NEU STATUS IN A TERTIARY CARE CENTRE OF EASTERN INDIA..

2019 ◽  
pp. 1-3
Author(s):  
Moumita Paul ◽  
Neepamanjari Barman* ◽  
Moumita Maiti ◽  
Ranu Sarkar
Keyword(s):  
Complex Disease ◽  
Histological Grade ◽  
Target Therapy ◽  
Tertiary Care ◽  
Response To Treatment ◽  
Treatment Modalities ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Tertiary Care Centre ◽  
Epidermal Growth

Background: Carcinoma of the breast is a truly complex disease with a large intratumoral heterogeneity, leading to markedly variable clinical course and response to treatment modalities. Prognosis and management of breast cancer are influenced by variables such as stage, grade, hormone receptor status of estrogen(ER), progesterone(PR) and Human epidermal growth factor receptor2 (HER2/neu) over expression. Aims and Objectives:To highlight the histomorphological spectrum of breast carcinomas and their ER,PR, HER2NEU status. And also to find out correlation between their histological grade and the hormone status . Materials and Methods - 115 breast carcinomas were clinicopathologically and immunohistochemically analyzed in which assessment of Her2/neu, ER, PR had been performed prospectively. Statistical analysis was then used to correlate the above observation. Conclusion: This study highlights the importance of histopathology and immunohistochemistry in breast cancers not only in diagnosing the lesion but also in predicting the prognosis and target therapy.

scholarly journals Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer

2021 ◽  
Author(s):  
E. Amiri Souri ◽  
A. Chenoweth ◽  
A. Cheung ◽  
S. N. Karagiannis ◽  
S. Tsoka
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Clinical Decision Making ◽  
Histological Grade ◽  
Tumour Size ◽  
Clinical Decision ◽  
Gene Signature ◽  
Risk Classification ◽  
Breast Cancers ◽  
Grade 3

Abstract Background Prognostic stratification of breast cancers remains a challenge to improve clinical decision making. We employ machine learning on breast cancer transcriptomics from multiple studies to link the expression of specific genes to histological grade and classify tumours into a more or less aggressive prognostic type. Materials and methods Microarray data of 5031 untreated breast tumours spanning 33 published datasets and corresponding clinical data were integrated. A machine learning model based on gradient boosted trees was trained on histological grade-1 and grade-3 samples. The resulting predictive model (Cancer Grade Model, CGM) was applied on samples of grade-2 and unknown-grade (3029) for prognostic risk classification. Results A 70-gene signature for assessing clinical risk was identified and was shown to be 90% accurate when tested on known histological-grade samples. The predictive framework was validated through survival analysis and showed robust prognostic performance. CGM was cross-referenced with existing genomic tests and demonstrated the competitive predictive power of tumour risk. Conclusions CGM is able to classify tumours into better-defined prognostic categories without employing information on tumour size, stage, or subgroups. The model offers means to improve prognosis and support the clinical decision and precision treatments, thereby potentially contributing to preventing underdiagnosis of high-risk tumours and minimising over-treatment of low-risk disease.

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17

Cancer ◽  
2010 ◽  
Vol 117 (1) ◽  
pp. 48-53 ◽  
Author(s):  
Semir Vranic ◽  
Bryan Teruya ◽  
Susan Repertinger ◽  
Pamela Ulmer ◽  
Jill Hagenkord ◽  
...  
Keyword(s):  
Chromosome 17 ◽  
Breast Carcinomas ◽  
Her2 Gene ◽  
Gene Status

Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory

2016 ◽  
Vol 70 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Carla Thomas ◽  
Cleo Robinson ◽  
Ben Dessauvagie ◽  
Benjamin Wood ◽  
Greg Sterrett ◽  
...  
Keyword(s):  
Gene Expression ◽  
Breast Carcinoma ◽  
Expression Profiling ◽  
Proliferative Activity ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Ki 67 ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Formalin Fixed

AimBreast carcinoma proliferative activity, histological grade and commercial molecular tests are all important in prognostication and treatment. There is a particular need for improved, standardised techniques for subclassification of grade 2 breast cancers into low-risk and high-risk prognostic groups. In this study we investigated whether gene expression profiling of five proliferation genes was feasible using breast cancer tissue in a clinical setting and whether these profiles could enhance pathological assessment.MethodsExpression of five proliferation gene mRNAs; Ki-67, STK 15, CCNB1, CCND1 and MYBL2, was quantified in 27 breast carcinomas and compared with Ki-67 proliferation index (PI) and Nottingham mitotic score.ResultsExpression of Ki-67, STK15 and MYBL2 mRNA showed moderate Spearman's correlation with Ki-67 PI (p<0.01), but CCND1 and CCNB1 showed weak, non-significant correlation. Individual gene expression did not associate with mitotic score but combined mRNA expression correlated with both Ki-67 PI (p=0.018) and mitotic score (p=0.03; 0.007).ConclusionsThis study confirms mRNA analysis in breast carcinoma formalin-fixed, paraffin-embedded samples is feasible and suggests gene expression profiling, using a small set of five proliferation genes, has potential in aiding histological grading or assessment of proliferative activity of breast cancers. To fully evaluate the clinical applicability of this approach, a larger cohort study with long-term follow-up data is required.

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

2021 ◽  
pp. 41-44
Author(s):  
R. Rani Suganya ◽  
M. Annapoorani ◽  
C. Naveen Kumar
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Hormone Receptor ◽  
Histological Grade ◽  
Systemic Disease ◽  
Lymph Node Involvement ◽  
Hormone Receptor Status ◽  
Major Health Problem ◽  
Receptor Status ◽  
Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

Sign in / Sign up

Export Citation Format

Share Document